<?xml version="1.0" encoding="UTF-8"?><measure><measureDetails><uuid>40280381-4b9a-3825-014b-bd61148f05c9</uuid><title>Oncology: Medical and Radiation - Pain Intensity Quantified</title><shortTitle>Onc_Pain-Int-Quant</shortTitle><emeasureid>157</emeasureid><guid>9a0330d0-3d9b-11e1-8634-00237d5bf174</guid><version>4.0.000</version><nqfid extension="0384" root="2.16.840.1.113883.3.560.1"/><period calenderYear="true" uuid="8a4d92b2-3946-cdae-0139-77ee251a6411"><startDate>00000101</startDate><stopDate>00001231</stopDate></period><steward id="2.16.840.1.113883.3.526">American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)</steward><developers><developer id="2.16.840.1.113883.3.526">American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)</developer></developers><endorsement id="2.16.840.1.113883.3.560">National Quality Forum</endorsement><description>Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified</description><copyright>Copyright 2014 American Medical Association. All Rights Reserved.</copyright><disclaimer>Physician Performance Measures (Measures) and related data specifications have been developed by the American Medical Association (AMA) - convened Physician Consortium for Performance Improvement(R) (PCPI[R]). These Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA, (on behalf of the PCPI). Neither the AMA, PCPI nor its members shall be responsible for any use of the Measures. &#xD;
&#xD;
THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. &#xD;
&#xD;
Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT[R]) or other coding contained in the specifications. &#xD;
&#xD;
CPT(R) contained in the Measure specifications is copyright 2004-2014 American Medical Association. LOINC(R) copyright 2004-2014 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2014 International Health Terminology Standards Development Organisation. ICD-10 copyright 2014 World Health Organization. All Rights Reserved.&#xD;
&#xD;
Due to technical limitations, registered trademarks are indicated by (R) or [R].</disclaimer><scoring id="PROPOR">Proportion</scoring><types><type id="PROCESS">Process</type></types><componentMeasures/><itemCount><elementRef dataType="Encounter, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a640f" name="Office Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1001"/><elementRef dataType="Encounter, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a641a" name="Face-to-Face Interaction" oid="2.16.840.1.113883.3.464.1003.101.12.1048"/><elementRef dataType="Procedure, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a6413" name="Radiation Treatment Management" oid="2.16.840.1.113883.3.526.3.1026"/></itemCount><stratification>None</stratification><riskAdjustment>None</riskAdjustment><aggregation>None</aggregation><rationale>Inadequate cancer pain management is widely prevalent, harmful to the patient and costly.</rationale><recommendations>This algorithm begins with the premise that all patients with cancer should be screened for pain during the initial evaluation, follow-up intervals, and whenever new therapy is initiated. If pain is present on a screening evaluation, the pain intensity must be quantified by the patient (whenever possible). Since pain is inherently subjective, patients' self-reporting of pain is the current standard of care for assessment. (NCCN, 2014)&#xD;
&#xD;
Intensity of pain should be quantified using a numerical rating scale (ie, 0-10), visual analog scale, categorical scale, or pictorial scale (eg, The Faces Pain Rating Scale). Although pain is commonly assessed using numerical or categorical ratings, some patients may experience difficulty with these scales. The Faces Pain Rating Scale may be successful with patients who have difficulty with other scales, for example, children, the elderly, and patients with language or cultural differences or other communication barriers. (NCCN, 2014)&#xD;
&#xD;
All patients should be routinely screened for pain, and when it is present, pain intensity should be recorded in highly visible ways that facilitate regular review by health care providers. A standard for pain assessment and documentation should be established in each setting to ensure that pain is recognized, documented, and treated promptly. (APS, 2005)</recommendations><improvementNotations>Higher score indicates better quality</improvementNotations><references><reference>National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Adult Cancer Pain. Version 2.2014. Available at: http://www.nccn.org.</reference><reference>Gordon DB; Dahl JL, Miaskowski C, et al. American Pain Society Recommendations for Improving the Quality of Acute and Cancer Pain Management: American Pain Society Quality of Care Task Force. Arch Intern Med. 2005;165:1574-1580.</reference></references><definitions>None</definitions><guidance>This measure is an episode-of-care measure; the level of analysis for this measure is every visit for patients with a diagnosis of cancer who are also receiving chemotherapy or radiation therapy during the measurement period. For patients receiving radiation therapy, pain intensity should be quantified at each radiation treatment management encounter. For patients receiving chemotherapy, pain intensity should be quantified at each face-to-face encounter with the physician while the patient is receiving treatment. For purposes of calculating this measure, eligible encounters for patients receiving chemotherapy will include those encounters where the patient has been administered chemotherapy within 30 days prior to the encounter and also been administered chemotherapy within 30 days after the date of the encounter. For example, at every visit for patients with a diagnosis of cancer who are also receiving chemotherapy or radiation therapy, the patient should have pain intensity quantified.&#xD;
&#xD;
Pain intensity should be quantified using a standard instrument, such as a 0-10 numeric rating scale, visual analog scale, a categorical scale, or the pictorial scale.</guidance><transmissionFormat>TBD</transmissionFormat><initialPopDescription>All patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy</initialPopDescription><denominatorDescription>Equals Initial Population</denominatorDescription><denominatorExclusionsDescription>None</denominatorExclusionsDescription><numeratorDescription>Patient visits in which pain intensity is quantified</numeratorDescription><numeratorExclusionsDescription>Not Applicable</numeratorExclusionsDescription><denominatorExceptionsDescription>None</denominatorExceptionsDescription><measurePopulationDescription>Not Applicable</measurePopulationDescription><measurePopulationExclusionsDescription>Not Applicable</measurePopulationExclusionsDescription><measureObservationsDescription>Not Applicable</measureObservationsDescription><supplementalData>For every patient evaluated by this measure also identify payer, race, ethnicity and sex.</supplementalData><qualityMeasureSet uuid="c8a52f26-3807-4a84-96ba-cebc5d7640c1">None</qualityMeasureSet>
<finalizedDate value="201503302145-0500"/>
</measureDetails><supplementalDataElements><elementRef id="8a4d92b2-3946-cdae-0139-77ee251a641b" name="ONC Administrative Sex"/><elementRef id="8a4d92b2-3946-cdae-0139-77ee251b641c" name="Race"/><elementRef id="8a4d92b2-3946-cdae-0139-77ee251b641d" name="Ethnicity"/><elementRef id="8a4d92b2-3946-cdae-0139-77ee251b641e" name="Payer"/></supplementalDataElements><riskAdjustmentVariables/><subTreeLookUp><subTree displayName="OVorF2FEncounter" qdmVariable="true" uuid="34A42710-58DF-433B-91D3-4E2C66E00797"><relationalOp displayName="During" type="DURING"><setOp displayName="UNION" type="union"><elementRef displayName="Office Visit : Encounter, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a640f" type="qdm"/><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a641a" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="8a4d92b2-3946-cdae-0139-77ee251a6411" type="qdm"/></relationalOp></subTree><subTree displayName="Occurrence A of $OVorF2FEncounter" instance="A" instanceOf="34A42710-58DF-433B-91D3-4E2C66E00797" qdmVariable="true" uuid="ADB3ACA4-2936-4A77-B9CB-3DF7B876C545"><relationalOp displayName="During" type="DURING"><setOp displayName="UNION" type="union"><elementRef displayName="Office Visit : Encounter, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a640f" type="qdm"/><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a641a" type="qdm"/></setOp><elementRef displayName="Measurement Period : Timing Element" id="8a4d92b2-3946-cdae-0139-77ee251a6411" type="qdm"/></relationalOp></subTree><subTree displayName="RadiationTreatmentManagement" qdmVariable="true" uuid="571F1D0D-C2ED-4B7D-9A4D-6ADE6987E3EA"><relationalOp displayName="During" type="DURING"><elementRef displayName="Radiation Treatment Management : Procedure, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a6413" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="8a4d92b2-3946-cdae-0139-77ee251a6411" type="qdm"/></relationalOp></subTree><subTree displayName="Occurrence A of $RadiationTreatmentManagement" instance="A" instanceOf="571F1D0D-C2ED-4B7D-9A4D-6ADE6987E3EA" qdmVariable="true" uuid="E1886761-B271-4256-A963-7961BCDE85E2"><relationalOp displayName="During" type="DURING"><elementRef displayName="Radiation Treatment Management : Procedure, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a6413" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="8a4d92b2-3946-cdae-0139-77ee251a6411" type="qdm"/></relationalOp></subTree><subTree displayName="Chemo SAE OVorF2F" qdmVariable="false" uuid="5DA42FE4-12DE-4828-AF7E-B99AE66E9509"><relationalOp displayName="&lt;= 30 days Starts After End Of" operatorType="Less Than or Equal To" quantity="30" type="SAE" unit="days"><elementRef displayName="Chemotherapy Administration : Procedure, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a6412" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="ADB3ACA4-2936-4A77-B9CB-3DF7B876C545" type="subTree"/></relationalOp></subTree><subTree displayName="Chemo SBE OVorF2F" qdmVariable="false" uuid="2184188C-C4EE-4D34-9D9C-658D1FBBD7FB"><relationalOp displayName="&lt;= 30 days Starts Before End Of" operatorType="Less Than or Equal To" quantity="30" type="SBE" unit="days"><elementRef displayName="Chemotherapy Administration : Procedure, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a6412" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="ADB3ACA4-2936-4A77-B9CB-3DF7B876C545" type="subTree"/></relationalOp></subTree><subTree displayName="Cancer Dx Overlaps Visit" qdmVariable="false" uuid="DCF14E63-0A7D-4CE9-B163-431783BF093C"><relationalOp displayName="Overlaps" type="Overlap"><elementRef displayName="Cancer : Diagnosis, Active" id="8a4d92b2-3946-cdae-0139-77ee251a6414" type="qdm"/><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="ADB3ACA4-2936-4A77-B9CB-3DF7B876C545" type="subTree"/></relationalOp></subTree><subTree displayName="Cancer Overlaps RadiationTreatmentManagement" qdmVariable="false" uuid="032CE38F-452C-455D-8BCF-299A388E15E9"><relationalOp displayName="Overlaps" type="Overlap"><elementRef displayName="Cancer : Diagnosis, Active" id="8a4d92b2-3946-cdae-0139-77ee251a6414" type="qdm"/><subTreeRef displayName="Occurrence A of RadiationTreatmentManagement" id="E1886761-B271-4256-A963-7961BCDE85E2" type="subTree"/></relationalOp></subTree><subTree displayName="SPAT During OVorF2F" qdmVariable="false" uuid="31450C08-190F-4EFE-9B82-9646DE2555D2"><relationalOp displayName="During" type="DURING"><elementRef displayName="Standardized Pain Assessment Tool : Risk Category Assessment" id="8a4d92b2-3946-cdae-0139-77ee251a6415" type="qdm"><attribute attrUUID="6b261aca-0966-4361-aacb-73fa38a57405" mode="Check if Present" name="result"/></elementRef><subTreeRef displayName="Occurrence A of OVorF2FEncounter" id="ADB3ACA4-2936-4A77-B9CB-3DF7B876C545" type="subTree"/></relationalOp></subTree><subTree displayName="SPAT During Radiation Treatment Management" qdmVariable="false" uuid="BAAE7EEC-4978-4E15-9CCC-08704857AB11"><relationalOp displayName="During" type="DURING"><elementRef displayName="Standardized Pain Assessment Tool : Risk Category Assessment" id="8a4d92b2-3946-cdae-0139-77ee251a6415" type="qdm"><attribute attrUUID="b5403e9f-75d8-4da4-ab79-f26760e01442" mode="Check if Present" name="result"/></elementRef><subTreeRef displayName="Occurrence A of RadiationTreatmentManagement" id="E1886761-B271-4256-A963-7961BCDE85E2" type="subTree"/></relationalOp></subTree></subTreeLookUp><measureGrouping><group sequence="1"><clause displayName="Initial Population 1" type="initialPopulation" uuid="CC7E2F42-504C-4C8B-BBFE-B6DB0612B6A4"><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><comment displayName="comment" type="comment"/><logicalOp displayName="AND" type="and"><subTreeRef displayName="Cancer Dx Overlaps Visit" id="DCF14E63-0A7D-4CE9-B163-431783BF093C" type="subTree"/><subTreeRef displayName="Chemo SBE OVorF2F" id="2184188C-C4EE-4D34-9D9C-658D1FBBD7FB" type="subTree"/><subTreeRef displayName="Chemo SAE OVorF2F" id="5DA42FE4-12DE-4828-AF7E-B99AE66E9509" type="subTree"/></logicalOp><subTreeRef displayName="Cancer Overlaps RadiationTreatmentManagement" id="032CE38F-452C-455D-8BCF-299A388E15E9" type="subTree"/></logicalOp></logicalOp></clause><clause displayName="Denominator 1" type="denominator" uuid="FCABC394-C505-4F3D-8198-A7AE0E849D63"><logicalOp displayName="AND" type="and"/></clause><clause displayName="Numerator 1" type="numerator" uuid="39B35A64-F6E9-40A8-9F70-45E7559B3514"><logicalOp displayName="AND" type="and"><comment displayName="comment" type="comment"/><logicalOp displayName="OR" type="or"><comment displayName="comment" type="comment"/><subTreeRef displayName="SPAT During OVorF2F" id="31450C08-190F-4EFE-9B82-9646DE2555D2" type="subTree"/><subTreeRef displayName="SPAT During Radiation Treatment Management" id="BAAE7EEC-4978-4E15-9CCC-08704857AB11" type="subTree"/></logicalOp></logicalOp></clause><clause displayName="denominatorExclusions" type="denominatorExclusions" uuid="7a604dc7-79c4-4140-b0c2-1c94dbeb2b7f"><logicalOp displayName="AND" type="and"/></clause><clause displayName="numeratorExclusions" type="numeratorExclusions" uuid="e10c6c5a-4ef7-4515-9d40-662dee8b1a5d"><logicalOp displayName="AND" type="and"/></clause><clause displayName="denominatorExceptions" type="denominatorExceptions" uuid="0665905f-2e51-4343-aac2-c1c16be5ddea"><logicalOp displayName="AND" type="and"/></clause><clause displayName="stratum" type="stratum" uuid="27e77e50-6548-4ef6-bc79-4722917e2ebe"/></group></measureGrouping><elementLookUp><qdm datatype="Patient Characteristic Birthdate" id="1307ea45-22a3-4552-945f-bb9a34a6d749" name="Birthdate" oid="21112-8" suppDataElement="false" taxonomy="SNOMED-CT" uuid="1307ea45-22a3-4552-945f-bb9a34a6d749" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnosis, Active" id="8a4d92b2-3946-cdae-0139-77ee251a6414" name="Cancer" oid="2.16.840.1.113883.3.526.3.1010" suppDataElement="false" taxonomy="Grouping" uuid="8a4d92b2-3946-cdae-0139-77ee251a6414" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a6412" name="Chemotherapy Administration" oid="2.16.840.1.113883.3.526.3.1027" suppDataElement="false" taxonomy="Grouping" uuid="8a4d92b2-3946-cdae-0139-77ee251a6412" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Ethnicity" id="8a4d92b2-3946-cdae-0139-77ee251b641d" name="Ethnicity" oid="2.16.840.1.114222.4.11.837" suppDataElement="true" taxonomy="CDCREC" uuid="8a4d92b2-3946-cdae-0139-77ee251b641d" version="1"/><qdm datatype="Patient Characteristic Expired" id="e0ac3488-17b3-4729-8bd6-b3c8b6a924c2" name="Expired" oid="419099009" suppDataElement="false" taxonomy="SNOMED-CT" uuid="e0ac3488-17b3-4729-8bd6-b3c8b6a924c2" version="1.0"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a641a" name="Face-to-Face Interaction" oid="2.16.840.1.113883.3.464.1003.101.12.1048" suppDataElement="false" taxonomy="Grouping" uuid="8a4d92b2-3946-cdae-0139-77ee251a641a" version="1.0"/><qdm codeSystemName="National Quality Forum" datatype="Timing Element" id="8a4d92b2-3946-cdae-0139-77ee251a6411" name="Measurement Period" oid="2.16.840.1.113883.3.67.1.101.1.53" suppDataElement="false" taxonomy="NQF" uuid="8a4d92b2-3946-cdae-0139-77ee251a6411" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a640f" name="Office Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1001" suppDataElement="false" taxonomy="Grouping" uuid="8a4d92b2-3946-cdae-0139-77ee251a640f" version="1"/><qdm codeSystemName="National Library of Medicine" datatype="Patient Characteristic Sex" id="8a4d92b2-3946-cdae-0139-77ee251a641b" name="ONC Administrative Sex" oid="2.16.840.1.113762.1.4.1" suppDataElement="true" taxonomy="AdministrativeGender" uuid="8a4d92b2-3946-cdae-0139-77ee251a641b" version="1"/><qdm codeSystemName="PHDSC" datatype="Patient Characteristic Payer" id="8a4d92b2-3946-cdae-0139-77ee251b641e" name="Payer" oid="2.16.840.1.114222.4.11.3591" suppDataElement="true" taxonomy="SOP" uuid="8a4d92b2-3946-cdae-0139-77ee251b641e" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Race" id="8a4d92b2-3946-cdae-0139-77ee251b641c" name="Race" oid="2.16.840.1.114222.4.11.836" suppDataElement="true" taxonomy="CDCREC" uuid="8a4d92b2-3946-cdae-0139-77ee251b641c" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="8a4d92b2-3946-cdae-0139-77ee251a6413" name="Radiation Treatment Management" oid="2.16.840.1.113883.3.526.3.1026" suppDataElement="false" taxonomy="Grouping" uuid="8a4d92b2-3946-cdae-0139-77ee251a6413" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Risk Category Assessment" id="8a4d92b2-3946-cdae-0139-77ee251a6415" name="Standardized Pain Assessment Tool" oid="2.16.840.1.113883.3.526.3.1028" suppDataElement="false" taxonomy="Grouping" uuid="8a4d92b2-3946-cdae-0139-77ee251a6415" version="1"/></elementLookUp></measure>